- Details
- Pedro Barata is joined by Maxime Meylan to discuss a key ancillary analysis of the phase II BIONIKK trial aimed at understanding immune markers predictive of the efficacy of immune checkpoint inhibition as first-line therapy in metastatic clear cell renal cell carcinoma (mccRCC). This analysis demonstrates that the number of tertiary lymphoid structures and ki67+PD1+ density likely predict the eff...
|
- Details
- Alicia Morgans engages in a discussion with Mohamad Allaf about the PROSPER Study, an ECOG investigation focused on a neoadjuvant perioperative approach to treating high-risk kidney cancer. The conversation delves into the study's rationale and design, exploring the collaboration between medical oncologists and urologists. Dr. Allaf details the premise of the study, highlighting the implementation...
|
- Details
- Alicia Morgans and Naomi Haas discuss the PROSPER Trial, focusing on the study design, results, and insights into kidney cancer treatment. The trial began from a collaboration at the Prostate Cancer Foundation meeting, leading to a two-arm study of 804 patients, exploring the effects of nivolumab preoperatively followed by surgery and adjuvant therapy, versus surgery alone. Unfortunately, the prim...
|
- Details
- Sarmad Sadeghi and Pedro Barata discuss the results of a randomized Phase II that explored OX40in combination with axitinib in patients with renal cell carcinoma. Patients in the trial had progressive disease after receiving immunotherapy with the usual PD-1/PD-L1 antibodies. The primary endpoint was progression-free survival. Dr. Sadeghi describes the rationale for the trial design, why the trial...
|
- Details
- Andrea Apolo, Pavlos Msaouel, and Petros Grivas discuss findings and recommendations shared during an ASCO presentation on clinical trial endpoints in the adjuvant setting for RCC kidney cancer and urothelial cancer. The conversation touches on trial design and efficacy, as well as concerns about treatment burden, toxicity, cost, and survival benefit. Patient advocacy and patient-specific issues r...
|
- Details
- Alicia Morgans speaks with Toni Choueiri about groundbreaking developments in the treatment of kidney cancer, particularly through the LITESPARK program. Dr. Choueiri outlines the successful integration of HIF-2α inhibitors like belzutifan into kidney cancer therapeutics, emphasizing the drug's promising durability and lack of new toxicities. The conversation pivots around the significance of the...
|
- Details
- Alicia Morgans is joined by Toni Choueiri in a discussion on the COSMIC-313 examining the role of triplet therapy with cabozantinib, nivolumab and ipilimumab as first-line treatment in patients with advanced renal cell carcinoma (RCC). The COSMIC-313 trial made strides at the 2022 ESMO meeting being a presidential symposium reporting the first phase 3 clinical trial in advanced RCC to use a contem...
|
- Details
- Ricardo Fernandes joins Pedro Barata in a discussion on PERFORM, an ongoing phase I study evaluating the safety of fecal microbiota transplantation (FMT) and immunotherapy combination in first-line (1L) metastatic renal cell carcinoma, and assessing whether FMT will prevent or mitigate immune-related adverse events. Dr. Fernandes details what led to the design and conduct of PERFORM. The study aim...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the OMNIVORE study published in the Journal of Clinical Oncology. This phase II response-adaptive trial investigated the rational application of immune checkpoint blockade in renal cell carcinoma. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zachary Klaassen, MD, MSc, Ur...
|
- Details
- Marc-Oliver Grimm joins Pedro Barata in a discussion on the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma (mRCC). The TITAN-RCC was designed many years ago, when nivolumab + ipilimumab (NIVO/IPI) was not approved yet as a first-line treatment. During this time the pivotal CheckMate 214 trial was still in pro...
|
